Evaluation of the performance of 5 commercialized enzyme immunoassays for the detection of Taenia solium antibodies and for the diagnosis of neurocysticercosis.

Autor: Carod JF; Institut Pasteur de Madagascar, BP 1274 Antananarivo 101, Madagascar. jfcarod@yahoo.es, Randrianarison M, Razafimahefa J, Ramahefarisoa RM, Rakotondrazaka M, Debruyne M, Dautigny M, Cazal P, Andriantseheno ML, Charles ER
Jazyk: angličtina
Zdroj: Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2012 Jan; Vol. 72 (1), pp. 85-9. Date of Electronic Publication: 2011 Nov 15.
DOI: 10.1016/j.diagmicrobio.2011.09.014
Abstrakt: This study aimed to evaluate 5 enzyme immunoassays for detecting human antibodies against Taenia solium in human serum and for the diagnosis of neurocysticercosis (NCC): DRG™, RIDASCREEN™, NOVATECH™, CYPRESS™, and IVD™. A collection of 114 reference serum samples were used. All sera were tested both by ELISA and by an immunoblot method (enzyme-linked immunoelectrotransfer blot [EITB]). When compared with EITB, the Ridascreen™ test had the best positive concordance rate (85.1-91.2%) and the NovaLisa test™ showed the optimal negative concordance rate (93.7-95.6%). All tests had a sensitivity under 72% and a specificity above 60%. The best sensitivity was obtained using Ridascreen™ test (71.4%). An optimal specificity was achieved by the NovaLisa test™. T. solium-positive sera all cross-reacted with E. granulosus positive samples. In the commercial assays evaluated here, the most appropriate ELISA test for screening may be the Ridascreen™ assay. Antibody detection seems to be not appropriate for NCC diagnosis because of its overall lack of sensitivity.
(Copyright © 2012 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: